Dermatology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
J Eur Acad Dermatol Venereol. 2010 Oct;24(10):1166-70. doi: 10.1111/j.1468-3083.2010.03611.x.
Despite numerous therapeutic modalities reported in the literature, treatment of common warts remains a continuing challenge and there is no universal consensus about optimal treatment. Recently, intralesional immunotherapy by different antigens has proved efficacy in the treatment of different types of warts.
To evaluate the efficacy and safety of intralesional mumps, measles and rubella (MMR) vaccine in the treatment of common warts.
The study included 135 patients with single or multiple recalcitrant or non-recalcitrant common warts. They were randomly assigned to two groups; the first group (85 patients) received intralesional MMR vaccine, and the second group (50 patients) received intralesional saline as a control group. Both treatments were injected into single lesions or largest wart in case of multiple lesions at 2-week intervals until complete clearance or for a maximum of five treatments. Follow-up was made every 2 months for 6 months to detect any recurrence.
A highly significant difference was found between the therapeutic response of common warts to MMR vaccine and saline control group (P < 0.001). In the MMR group, complete response was achieved in 80% and 84.6% of patients presenting with recalcitrant and multiple warts respectively. No recurrence was observed in the MMR group and side effects included pain during injection and flu-like symptoms.
Intralesional immunotherapy by MMR vaccine is a promising effective and safe treatment modality for common warts, particularly the multiple ones.
尽管文献中有许多治疗方法报道，但寻常疣的治疗仍然是一个持续的挑战，对于最佳治疗方法尚未达成普遍共识。最近，不同抗原的皮内免疫疗法已被证明对不同类型的疣有效。
评估皮内腮腺炎、麻疹和风疹（MMR）疫苗治疗寻常疣的疗效和安全性。
该研究纳入了 135 名单发或多发难治性或非难治性寻常疣患者。他们被随机分为两组；第一组（85 名患者）接受皮内 MMR 疫苗治疗，第二组（50 名患者）接受皮内生理盐水作为对照组。两种治疗均在 2 周间隔内注射到单个皮损或最大的疣中，如果是多发性皮损，则注射到最大的一个皮损中，直到完全清除或最多进行 5 次治疗。在接下来的 6 个月中，每 2 个月进行一次随访，以检测任何复发情况。
寻常疣对 MMR 疫苗和生理盐水对照组的治疗反应有显著差异（P<0.001）。在 MMR 组中，难治性和多发性疣患者的完全缓解率分别达到 80%和 84.6%。在 MMR 组中未观察到复发，副作用包括注射时疼痛和流感样症状。
皮内 MMR 疫苗免疫疗法是一种有前途的有效且安全的寻常疣治疗方法，尤其是多发性寻常疣。
